A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B

Modern Rheumatology

Volumn 21, Issue 6, 2011, Pages 701-705

  Tsuboi, Hideki ^a   Tsujii, Akira ^b   Nampei, Akihide ^b   Yoshihara, Harumasa ^b   Kawano, Kiyoshi ^b   Takeuchi, Eiji ^c   Shi, Kenrin ^d  

^a MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis B; Infliximab; Lamivudine; Rheumatoid arthritis; Tocilizumab

Indexed keywords

GLYCYRRHIZIC ACID; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; MIZORIBINE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; INFECTION PREVENTION; MEDICAL HISTORY; PHLEGMON; PRIORITY JOURNAL; REMISSION; RETREATMENT; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HUMANS; LAMIVUDINE; MIDDLE AGED; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84855681277     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0470-3     Document Type: Article

References (18)

1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologicand biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84. (Pubitemid 351847559)
2. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140:659-62.
3. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498-502.
4. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686-7. (Pubitemid 36760576)
5. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol. 2003;30:1624-5. (Pubitemid 36835467)
6. Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol. 2008;14:245-6.
7. Verhelst X, Orlent H, Colle I, Geerts A, de Vos M, van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol. 2010;22:494-9.
8. Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol. 2010. doi: 10.1007/s10067-010-1438-y [Epub ahead of print].
9. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-αlpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford). 2006;45:1294-7. (Pubitemid 44542073)
10. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum. 2008;38:208-17.
11. Kuroda T, Wada Y, Kobayashi D, Sato H, Murakami S, Nakano M, et al. Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: A review of the literature. Rheumatol Int. 2010. doi:10.1007/s00296-009-1344-2 [Epub ahead of print].
12. Robinson H, Walker-Bone K. Anti-TNF-αlpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford). 2009;48:448-50.
13. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factoralpha (TNF-αlpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: A retrospective record review of 11 patients. Clin Rheumatol. 2009;28:787-91.
14. Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis. 2005;64:788-9. (Pubitemid 40559316)
15. Ogawa J, Harigai M, Akashi T, Nagasaka K, Suzuki F, Tominaga S, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis. 2006;65:1667-9. (Pubitemid 44799688)
16. Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford). 2008;47:1838-40.
17. Galun E, Nahor O, Eid A, Jurim O, Rose-John S, Blum HE, et al. Human interleukin-6 facilitates hepatitis B virus infection in vitro and in vivo. Virology. 2000;270:299-309. (Pubitemid 30333677)
18. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766-70.